Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
12/1/1999
 
First Published:
4/1/1999
1.
Phase III Study of IDEC-Y2B8 in Patients With Progressive Follicular B-Cell Non-Hodgkin's Lymphoma That is Refractory to Prior Rituximab Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
IDEC-106-06
MAYO-987804, UCLA-9808026
Last Modified:
1/1/2000
 
First Published:
11/1/1999
2.
Phase II Study of Ibritumomab Tiuxetan (IDEC-Y2B8) Radioimmunotherapy in Patients with Relapsed or Refractory, Low Grade or B-Cell, Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
UCLA-9804024
IDEC-106-05, NCI-G99-1614
Last Modified:
6/1/2002
 
First Published:
5/1/2000
3.
Phase II Study of Rituximab and Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Relapsed or Refractory, Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
UAB-9930
GUMC-00095, IDEC-106-98, NCI-G00-1731, NCT00005592
Last Modified:
10/23/2008
 
First Published:
3/24/2003
4.
Phase II Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Patients Age 60 and Over With Previously Untreated Diffuse Large B-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Closed
60 and over
NCI
MSKCC-02090
NCT00058422
Last Modified:
9/25/2007
 
First Published:
5/1/2002
5.
Phase I Study of Rituximab Followed By Yttrium Y 90 Ibritumomab Tiuxetan With or Without Autologous Peripheral Blood Stem Cell Transplantation in Children With Recurrent or Refractory CD20-Positive Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
Under 22
NCI
COG-ADVL0013
NCT00036855, ADVL0013
Last Modified:
10/30/2007
 
First Published:
2/16/2007
6.
Phase I Study of CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With CD20+ Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Diagnostic, Treatment
Closed
18 and over
NCI
MAYO-LS0382
MAYO-IRB-703-04, NCT00438880
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute